read following abstract graham emslie company i went ahead highlighted points interest objective safety efficacy tolerability venlafaxine extended release er subjects ages years major depressive disorder evaluated two multicenter randomized double blind placebo controlled trials conducted october august method participants received venlafaxine er flexible dose based body weight intent treat placebo intent treat weeks primary efficacy variable change baseline children depression rating scale revised score week results statistically significant differences venlafaxine er placebo children depression rating scale revised either study post hoc age subgroup analysis pooled data showed greater improvement children depression rating scale revised venlafaxine er placebo versus p among adolescents ages among children ages common adverse events anorexia abdominal pain hostility suicide related events common venlafaxine er treated participants placebo treated participants completed suicides conclusions venlafaxine er may effective depressed adolescents however safety efficacy pediatric patients established prescribers monitor signs suicidal ideation hostility pediatric patients taking venlafaxine er gripes ok studies conducted getting published delaying bad news studies positive findings would published years ago suicidal ideation suicidal attempt suicide preparation taking venlafaxine taking placebo numbers come latest jama analysis table grasping straws one analysis finds adolescents bit better drug decide run finding consistent across various rating scales one one scale initial guess difference also rather small magnitude i able address issues soon i get hands article library subscribes journal online april issue somehow yet arrived come